The future of the new GHTF: growing pains ahead?
This article was originally published in RAJ Devices
Regulators have called it a day for their collaboration with the industry in the Global Harmonization Task Force for medical devices and instead are seeking to develop "a regulator-led harmonisation and collaboration group"1,2. Is this development an acknowledgment of the growing importance of the work or of the growing criticism that regulators are too close to industry? Or is it both?
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.